VHL and melanoma: Lack of VHL, which usually marks HIF-1α for proteosomal destruction [57], could promote a pseudo-hypoxic or low ‘oxotype’ and a glycolytic phenotype in melanoma through HIF1α stabilization and increased expression of, e.g., the Glut-1 transporter and glycolytic enzymes [39, 40].